Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)

v3.24.0.1
Royalty and Commercial Payment Purchase Agreements - Bioasis (Details) - USD ($)
 12 Months Ended
Jun. 20, 2023
Nov. 02, 2020
Feb. 25, 2019
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Dec. 31, 2021
Agreements              
Contingent consideration under RPAs, AAAs and CPPAs       $ 7,000,000 $ 75,000    
Payments of consideration under RPAs, AAAs and CPPAs       14,650,000 8,000,000    
Long-term royalty and commercial payment receivables       57,952,000 63,683,000   $ 69,075,000
Bioasis              
Agreements              
Decrease in long-term royalty and commercial rights receivables due to impairment       1,575,000      
Bioasis | Royalty Purchase Agreement              
Agreements              
Acquisition of royalty and commercial payment receivables, Long-Term   $ 1,200,000 $ 400,000        
Contingent consideration under RPAs, AAAs and CPPAs     $ 75,000 0 $ 75,000 $ 0  
Payments of consideration under RPAs, AAAs and CPPAs   $ 1,200,000          
Impairment charge, Long-term royalty receivable $ 1,600,000            
Long-Term Right Receivable, Non-Current, Credit Loss Expense, Statement of Income or Comprehensive Income Impairment charges (Note 4, Note 5)            
Decrease in long-term royalty and commercial rights receivables due to impairment $ 1,600,000            
Amount of allowance for credit losses       $ 0